Abbott Settles Portion of Preterm Infant Formula Litigation for $670 Million — Abbott Laboratories

Event summary

Abbott reaches agreements to resolve the Gill case and claims involving approximately 2,000 individuals for $670 million.
The settlement follows a $495 million jury award in the Gill case, which Abbott appealed but was denied.
Approximately 1,700 lawsuits remain pending, involving claims on behalf of around 12,700 infants.
Courts have recently ruled in favor of preterm formula manufacturers, applying the learned intermediary doctrine.
Abbott maintains that preterm infant formulas are safe and necessary, supported by federal health authorities and medical professionals.

The big picture

Abbott's settlement of $670 million to resolve a portion of litigation involving its preterm infant formulas highlights the ongoing legal challenges faced by manufacturers in this critical healthcare segment. The resolution comes amid a series of favorable court rulings for preterm formula manufacturers, underscoring the strategic importance of the learned intermediary doctrine in defending against such claims. The broader industry dynamics involve ensuring continued access to these essential products, as disruptions could have significant consequences for neonatal care.

What we're watching

Legal Strategy: Whether Abbott's settlement strategy will encourage other manufacturers to resolve pending litigation similarly.
Regulatory Compliance: How federal health authorities and medical professionals will continue to support the safety and necessity of preterm infant formulas amid ongoing litigation.
Industry Dynamics: The pace at which the remaining 1,700 lawsuits will be resolved and their potential impact on the preterm infant formula market.